Keep up with
from Biogen Idec Hemophilia and
the issues that matter to the community.
Sign Up Today!
Research & Development Pipeline
We have completed late-stage clinical trials (Phase III) that evaluated recombinant factor VIII (referred to as rFVIIIFc) and recombinant factor IX (referred to as rFIXFc). The U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Applications (BLAs) for rFVIIIFc and rFIXFc. The applications are currently under review at FDA.